ITGR Integer (ITGR) Insider Trading, Ownership & Congress Trades
Medical Devices · Electromedical & electrotherapeutic apparatus · CIK 0001114483
Activist 13DForm 144 · 3
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
152
13F, latest reported quarter
Conversions, 180 days
5
Codes C/M, not in net · $0 priced
What the filings say about ITGR
Insiders, 180 days
-$5.2M net sold
2 sellers · 0% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$5.8M
3 notices
Activist stakes (13D), 180 days
1 filing
Largest: 14.0% of the class
Integer insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Integer Holdings Corp insiders sold a net $5.2M of stock across 46 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Sep 14, 2026.
- The trade is 164.5% of the 7,153 shares held after it.
- 1 other insider sold within 30 days.
- 152 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Human Resources Officer Thor Kirk K sold about $1.5M of ITGR on Sep 15, 2026; 1 other insider sold within 30 days and 152 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 104.5% of the 18,920 shares held after it.
- 1 other insider sold within 30 days.
- 152 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Human Resources Officer Thor Kirk K sold about $2.5M of ITGR on Sep 14, 2026, the largest insider sale at the company since 2025; 1 other insider sold within 30 days and 152 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on May 7, 2024.
- The trade is 174.1% of the 5,405 shares held after it.
- 1 other insider sold within 30 days.
- 152 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President, Growth & Innovation Senn Andrew sold about $1.2M of ITGR on Sep 8, 2026, the largest insider sale at the company since 2025; 1 other insider sold within 30 days and 152 funds added in the latest 13F quarter.Context
- 3 earlier Form 4 trades (code P or S) here by this insider (1 buy, 2 sales), the last on Nov 11, 2025.
- The trade is 18.8% of the 4,381 shares held after it.
- No other insider sold within 30 days.
- 152 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: VP, Corporate Controller Thomas Tommy P sold about $70.1K of ITGR on Mar 13, 2026; 152 funds added in the latest 13F quarter.Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on Jul 30, 2024.
- The trade is 27.2% of the 6,066 shares held after it.
- 3 other insiders bought within 30 days.
- 152 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP, Global Ops and Manufactur Harris John A bought about $115.5K of ITGR on Nov 12, 2025; 3 other insiders bought within 30 days and 152 funds added in the latest 13F quarter.46 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$5.2M over 180 days
-$5.2M over 90 days
below 77% of Medical Devices
Congress
no House purchase disclosed in the last 12 months
Funds
152 funds bought in last quarter
more than 76% of Medical Devices
Revenue
+8.0% year over year
below 56% of Medical Devices
Margin
5.5% net margin
more than 74% of Medical Devices
Buybacks
$50.0M repurchased, FY to 2026-07-03
more than 53% of Medical Devices
Short interest
10.8% of the float short (float per yahoo 2026-10-26) · 3.5 days to cover · settled 2026-09-30
more than 86% of Medical Devices
The situation: each line is one rule over one dataset
Tarheel Investors III L.P. disclosed a 5%+ stake (14.0%) in the last six months.
What changed in the last 30 days
Oct 13Tarheel Investors III L.P. filed a 13D for 14.0%
Oct 13Tarheel Investors III GP LLC filed a 13D for 14.0%
Oct 13KKR North America Fund XIV SCSp filed a 13D for 14.0%
Oct 13KKR Associates North America XIV SCSp filed a 13D for 14.0%
Oct 13KKR North America XIV S.a r.l. filed a 13D for 14.0%
Watch ITGR
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+71.2%12M
Insider buyInsider sell13D/G stakeForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns ITGR: institutional holders (13F)
13F holdings, latest reported quarter
5,353,741 sh
$500.3M
2,247,031 sh
$210.0M
2,040,469 sh
$190.7M
1,627,784 sh
$152.1M
1,554,450 sh
$145.3M
Congress trades in ITGR
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
13D: intends to influence · 13G: passive
Tarheel Investors III L.P.
Activist 13D · 2026-10-13
14.0%
Tarheel Investors III GP LLC
Activist 13D · 2026-10-13
14.0%
KKR North America Fund XIV SCSp
Activist 13D · 2026-10-13
14.0%
KKR Associates North America XIV SCSp
Activist 13D · 2026-10-13
14.0%
KKR North America XIV S.a r.l.
Activist 13D · 2026-10-13
14.0%
ITGR planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Thor Kirk K
Filed 2026-09-15
$593.6K
Thor Kirk K
Filed 2026-09-11
$4.0M
Senn Andrew
Filed 2026-09-08
$1.2M
ITGR mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
13D Activist Fund
$4.4M position · as of 2026-06-30
3.8%
Miller Intermediate Bond Fund
$4.8M position · as of 2026-07-31
2.9%
ABSOLUTE FLEXIBLE FUND
$971.2K position · as of 2026-06-30
2.4%
Invesco Small Cap Value Fund
$255.2M position · as of 2026-07-31
2.3%
Brown Advisory Small-Cap Fundamental Value Fund
$27.2M position · as of 2026-06-30
2.2%
Miller Convertible Bond Fund
$8.5M position · as of 2026-07-31
2.2%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Executive pay vs shareholder return · Joseph W. Dziedzic
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2024
$8.7M
$23.6M
n/a
+63%
+9%
2023
$8.7M
$25.2M
n/a
+22%
+0%
2022
$11.5M
$9.9M
n/a
-16%
-3%
2021
$6.9M
$6.0M
n/a
+5%
+21%
2020
$5.9M
$2.2M
$1.2M
+1%
+23%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
An activist crossed the 5% line with declared intent.
The record shows a net $5.2M sold by insiders over 180 days, 152 funds added last quarter, $5.8M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
ITGR financials
Revenue growth
+8.0%
XBRL, annual
Net margin
5.5%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$1.8B
four quarters, 2025-06-28 to 2026-07-03
Revenue, TTM ITGR
| FY Dec 2025 | $1.9B |
| FY Dec 2024 | n/a |
| FY Dec 2023 | $1.6B |
| FY Dec 2022 | $1.4B |
| FY Dec 2021 | $1.2B |
| Jul 2026 | $464.1M |
| Apr 2026 | $439.6M |
| Dec 2025 | $472.1M |
| Sep 2025 | $467.7M |
| Jun 2025 | $476.5M |
| Mar 2025 | $437.4M |
| Dec 2024 | $449.5M |
| Sep 2024 | $431.4M |
At each fiscal year end
Single quarter
Net margin, TTM
+7.0%
net income over revenue, 2025-06-28 to 2026-07-03
Net margin, TTM ITGR
| FY Dec 2025 | +5.5% |
| FY Dec 2024 | n/a |
| FY Dec 2023 | +5.7% |
| FY Dec 2022 | +4.8% |
| FY Dec 2021 | +7.9% |
| Jul 2026 | +5.1% |
| Apr 2026 | +3.8% |
| Dec 2025 | +10.3% |
| Sep 2025 | +8.5% |
| Jun 2025 | +7.8% |
| Mar 2025 | -5.1% |
| Dec 2024 | +7.3% |
| Sep 2024 | +8.2% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$112.0M
operating cash flow minus capex, 2025-06-28 to 2026-07-03
Free cash flow, TTM ITGR
| FY Dec 2025 | $105.1M |
| FY Dec 2024 | $99.8M |
| FY Dec 2023 | $60.3M |
| FY Dec 2022 | $41.7M |
| FY Dec 2021 | $103.2M |
| Jul 2026 | $37.0M |
| Apr 2026 | $737.0K |
| Dec 2025 | $27.9M |
| Sep 2025 | $46.3M |
| Jun 2025 | $24.9M |
| Mar 2025 | $6.1M |
| Dec 2024 | $44.1M |
| Sep 2024 | $45.5M |
At each fiscal year end
Single quarter
Debt to equity
0.72x
long-term 2026-07-03 plus current 2026-07-03; equity 2026-07-03
Debt to equity ITGR
| FY Dec 2025 | 0.68x |
| FY Dec 2024 | 0.61x |
| FY Dec 2023 | 0.63x |
| FY Dec 2022 | 0.65x |
| FY Dec 2021 | 0.61x |
| Jul 2026 | 0.72x |
| Apr 2026 | 0.74x |
| Dec 2025 | 0.68x |
| Sep 2025 | 0.68x |
| Jun 2025 | 0.71x |
| Mar 2025 | 0.77x |
| Dec 2024 | 0.61x |
| Sep 2024 | 0.67x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.17x
TTM operating cash flow over long-term 2026-07-03 plus current 2026-07-03
Cash flow to debt ITGR
| FY Dec 2025 | 0.17x |
| FY Dec 2024 | 0.21x |
| FY Dec 2023 | 0.19x |
| FY Dec 2022 | 0.13x |
| FY Dec 2021 | 0.19x |
| Jul 2026 | 0.17x |
| Apr 2026 | 0.15x |
| Dec 2025 | 0.17x |
| Sep 2025 | 0.17x |
| Jun 2025 | 0.17x |
| Mar 2025 | 0.17x |
| Dec 2024 | 0.21x |
| Sep 2024 | 0.18x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+7.5%
TTM net income over average of 2025-06-27 and 2026-07-03
Return on equity ITGR
| FY Dec 2025 | +6.1% |
| FY Dec 2024 | +7.6% |
| FY Dec 2023 | +6.2% |
| FY Dec 2022 | +4.8% |
| FY Dec 2021 | +7.4% |
| Jul 2026 | +7.5% |
| Apr 2026 | +8.6% |
| Dec 2025 | +6.1% |
| Sep 2025 | +5.2% |
| Jun 2025 | +5.1% |
| Mar 2025 | +4.9% |
| Dec 2024 | +7.6% |
| Sep 2024 | +7.4% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+3.8%
TTM net income over average of 2025-06-27 and 2026-07-03
Return on assets ITGR
| FY Dec 2025 | +3.2% |
| FY Dec 2024 | +4.0% |
| FY Dec 2023 | +3.2% |
| FY Dec 2022 | +2.5% |
| FY Dec 2021 | +3.9% |
| Jul 2026 | +3.8% |
| Apr 2026 | +4.2% |
| Dec 2025 | +3.2% |
| Sep 2025 | +2.6% |
| Jun 2025 | +2.5% |
| Mar 2025 | +2.4% |
| Dec 2024 | +4.0% |
| Sep 2024 | +3.8% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
+5.7%
operating income after a 5.9% effective tax rate, over long-term 2026-07-03 plus current 2026-07-03 plus average of 2025-06-27 and 2026-07-03 minus cash
Return on invested capital ITGR
| FY Dec 2025 | +6.4% |
| FY Dec 2024 | +6.8% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | +4.3% |
| FY Dec 2021 | +5.9% |
| Jul 2026 | +5.7% |
| Apr 2026 | +6.3% |
| Dec 2025 | +6.4% |
| Sep 2025 | +5.8% |
| Jun 2025 | +5.8% |
| Mar 2025 | +5.6% |
| Dec 2024 | +6.8% |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+5.6%
operating income (EBIT proxy) over average of 2025-06-27 and 2026-07-03 minus current liabilities
Return on capital employed ITGR
| FY Dec 2025 | +7.3% |
| FY Dec 2024 | +7.5% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | +4.5% |
| FY Dec 2021 | +5.9% |
| Jul 2026 | +5.6% |
| Apr 2026 | +6.5% |
| Dec 2025 | +7.3% |
| Sep 2025 | +7.3% |
| Jun 2025 | +7.4% |
| Mar 2025 | +7.3% |
| Dec 2024 | +7.5% |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
34.66x
close 2026-10-26 over four quarters of diluted EPS, 2025-06-28 to 2026-07-03
P/E, trailing ITGR
| FY Dec 2025 | 27.42x |
| FY Dec 2024 | 39.44x |
| FY Dec 2023 | 36.83x |
| FY Dec 2022 | 34.58x |
| FY Dec 2021 | 29.41x |
| Jul 2026 | 26.07x |
| Apr 2026 | 21.71x |
| Dec 2025 | 27.42x |
| Sep 2025 | 42.47x |
| Jun 2025 | 53.99x |
| Mar 2025 | 55.43x |
| Dec 2024 | 39.44x |
| Sep 2024 | 38.86x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$5.5B
market value at close 2026-10-26 on 2026-07-30 shares, plus long-term 2026-07-03 plus current 2026-07-03, minus cash 2026-07-03
Enterprise value ITGR
| FY Dec 2025 | $3.9B |
| FY Dec 2024 | $5.4B |
| FY Dec 2023 | $4.2B |
| FY Dec 2022 | $3.2B |
| FY Dec 2021 | $3.6B |
| Jul 2026 | $4.4B |
| Apr 2026 | $4.2B |
| Dec 2025 | $3.9B |
| Sep 2025 | $4.7B |
| Jun 2025 | $5.5B |
| Mar 2025 | $5.1B |
| Dec 2024 | $5.4B |
| Sep 2024 | $5.3B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+2.6%
TTM free cash flow over market value at close 2026-10-26
FCF yield ITGR
| FY Dec 2025 | +3.8% |
| FY Dec 2024 | +2.2% |
| FY Dec 2023 | +1.8% |
| FY Dec 2022 | +1.8% |
| FY Dec 2021 | +3.7% |
| Jul 2026 | +3.5% |
| Apr 2026 | +3.3% |
| Dec 2025 | +3.8% |
| Sep 2025 | +3.4% |
| Jun 2025 | +2.8% |
| Mar 2025 | +2.8% |
| Dec 2024 | +2.2% |
| Sep 2024 | +1.8% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
0.57x
P/E over trailing EPS growth of 61%: four quarters to 2026-07-03 against the four to 2025-06-27
PEG, trailing ITGR
| FY Dec 2025 | n/a |
| FY Dec 2024 | 1.58x |
| FY Dec 2023 | 1.03x |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jul 2026 | 0.43x |
| Apr 2026 | 0.24x |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | 1.58x |
| Sep 2024 | 1.21x |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $1.9B | $1.7B | $1.6B | $1.4B |
| Gross profit | $500.4M | $459.0M | $409.9M | $345.8M |
| Operating income | $221.3M | $208.2M | $163.3M | $112.7M |
| Net income | $102.8M | $119.9M | $90.7M | $66.4M |
| EPS (diluted) | 2.89 | 3.36 | 2.69 | 1.99 |
| Operating cash flow | $196.1M | $205.2M | $180.2M | $116.4M |
| Cash | $17.2M | $46.5M | $23.7M | $24.3M |
| Long-term debt | $1.2B | $980.2M | $959.9M | $907.1M |
| Buybacks | $50.0M | $0 | $0 | n/a |
SEC XBRL, fiscal years, as known on 2026-10-28
ITGR Stock Sonar score 6/7 axes
Find similar shapesCompareITGR ranks highest on institutional and government (76th percentile) and profitability (64th), and lowest on insider conviction (10th), among Medical Devices peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
ITGR filings, in plain words
Are Integer insiders buying or selling ITGR?
In the 180 days to 2026-10-28, Integer insiders were net sellers, a net $5.2M across purchases and sales reported on Form 4, by 2 sellers.
Are there planned insider sales of ITGR?
Yes. 3 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $5.8M of stock; the latest, by Thor Kirk K, was filed 2026-09-15.
Read the full summary
In the 180 days to 2026-10-28, Integer insiders were net sellers of ITGR, a net $5.2M across purchases and sales reported on Form 4 by 2 sellers. None of the 3 insider sales was flagged as made under a Rule 10b5-1 plan. Insiders filed 3 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $5.8M of stock. 1 activist Schedule 13D filing in the last 180 days declared an intent to influence the company, the largest for 14.0% of the class. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
